The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Mironovich O.L.

Federal State Budgetary Institution «Research Centre for Medical Genetics», Moscow, Russia, 115478

Bliznetz E.A.

Research Centre for Medical Genetics, Moscow, Russia

Garbaruk E.S.

Laboratory of Hearing and Speech, Academician I.P. Pavlov First Saint-Petersburg State Medical University, Saint-Petersburg, Russia, 197022

Belogurova M.B.

Saint Petersburg State Pediatric Medical University, Saint Petersburg, Russia, 194100;
N.N. Petrov Research Institute of Oncology, Saint Petersburg, Russia, 197758

Subora N.V.

N.N. Petrov Research Institute of Oncology, Saint Petersburg, Russia, 197758

Varfolomeyeva S.R.

Dmitry Rogachev National Research and Practical Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia

Kachanov D.Yu.

Dmitry Rogachev National Research and Practical Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia

Shamanskaya T.V.

Dmitry Rogachev Federal Scientific of Hematology, Oncology and Immunology, Moscow, Russia

Markova T.G.

FGU "Rossiĭskiĭ nauchno-prakticheskiĭ tsentr audiologii i slukhoprotezirovaniia"

Poliakov A.V.

Mediko-geneticheskiĭ nauchnyĭ tsentr RAMN, Moskva

The analysis of the association of the polymorphic variants of the TPMT, COMT, and ABCC3 genes with the development of hearing disorders induced by the cisplatin treatment

Authors:

Mironovich O.L., Bliznetz E.A., Garbaruk E.S., Belogurova M.B., Subora N.V., Varfolomeyeva S.R., Kachanov D.Yu., Shamanskaya T.V., Markova T.G., Poliakov A.V.

More about the authors

Journal: Russian Bulletin of Otorhinolaryngology. 2018;83(4): 60‑66

DOI: 10.17116/otorino201883460

Read: 1173 times

Download PDF (RU)
Contact the author
Table of contents

THE ANALYSIS OF THE ASSOCIATION OF THE POLYMORPHIC VARIANTS OF THE TPMT, COMT, AND ABCC3 GENES WITH THE DEVELOPMENT OF HEARING DISORDERS INDUCED BY THE CISPLATIN TREATMENT
THE ANALYSIS OF THE ASSOCIATION OF THE POLYMORPHIC VARIANTS OF THE TPMT, COMT, AND ABCC3 GENES WITH THE DEVELOPMENT OF HEARING DISORDERS INDUCED BY THE CISPLATIN TREATMENT

To cite this article:

Mironovich OL, Bliznetz EA, Garbaruk ES, et al. . The analysis of the association of the polymorphic variants of the TPMT, COMT, and ABCC3 genes with the development of hearing disorders induced by the cisplatin treatment. Russian Bulletin of Otorhinolaryngology. 2018;83(4):60‑66. (In Russ.)
https://doi.org/10.17116/otorino201883460

Подписка 2026 Вестник оториноларингологии (Russian Bulletin of Otorhinolaryngology)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Ototoxicity caused by anti-epileptic drugs. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):14-19
Abstract:

Cisplatin and its derivatives are widely used chemotherapeutic agents for the treatment of many cancers, including hepatoblastoma, brain tumors, and germ-cell tumors. This therapy contributed to the dramatic increase in the survival rate. However, its use is restricted by the high incidence of irreversible ototoxicity associated with cisplatin application (in more than 60% of the children receiving it). Some studies have reported that genetic variants of TPMT (rs 12201199), COMT (rs4646316), and ABCC3 (rs 1051640) are conferring increased risk of developing cisplatin-induced hearing loss. However, in other studies the results were not replicated. In the present study, we replicated the previous studies based on an independent cohort of Russian patients. SNP genotypes for rs 12201199, rs4646316 and rs 1051640 were determined in DNA samples obtained from 16 patients who developed hearing loss and a group of 34 patients whose hearing was retained. The association between TPMT (rs 12201199), COMT (rs4646316), and ABCC3 (rs 1051640) variants and the hearing loss was not observed in our cohort.

Keywords:

cisplatin
ototoxicirty
TPMT
COMT
ABCC3

Authors:

Mironovich O.L.

Federal State Budgetary Institution «Research Centre for Medical Genetics», Moscow, Russia, 115478

Bliznetz E.A.

Research Centre for Medical Genetics, Moscow, Russia

Garbaruk E.S.

Laboratory of Hearing and Speech, Academician I.P. Pavlov First Saint-Petersburg State Medical University, Saint-Petersburg, Russia, 197022

Belogurova M.B.

Saint Petersburg State Pediatric Medical University, Saint Petersburg, Russia, 194100;
N.N. Petrov Research Institute of Oncology, Saint Petersburg, Russia, 197758

Subora N.V.

N.N. Petrov Research Institute of Oncology, Saint Petersburg, Russia, 197758

Varfolomeyeva S.R.

Dmitry Rogachev National Research and Practical Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia

Kachanov D.Yu.

Dmitry Rogachev National Research and Practical Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia

Shamanskaya T.V.

Dmitry Rogachev Federal Scientific of Hematology, Oncology and Immunology, Moscow, Russia

Markova T.G.

FGU "Rossiĭskiĭ nauchno-prakticheskiĭ tsentr audiologii i slukhoprotezirovaniia"

Poliakov A.V.

Mediko-geneticheskiĭ nauchnyĭ tsentr RAMN, Moskva

Close metadata

References:

  1. Pal’chun VT, Kryukov AI. Otolaringologiya. Rukovodstvo dlya vrachei. M.: Meditsina. 2001. (InRuss.)
  2. Stakhovskaya OA. Ototoksichnost’ tsisplatina i puti ee profilaktiki pri lechenii zlokachestvennykh opukholei u detei: Dis... kand. med. nauk. M. 2002. (InRuss.)
  3. Algoritmy diagnostiki i lecheniya zlokachestvennykh novoobrazovanii. 2-e izd., pererab. i dop. Pod red. Chissova V.I. M.: MNIOI im. P.A. Gertsena; 2010. (In Russ.)
  4. Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur J Cancer. 2004;40:2445-2451. https://doi.org/10.1016/j.ejca.2003.08.009
  5. Coradini PP, Cigana L, Selistre SG, Rosito LS, Brunetto AL. Ototoxicity from cisplatin therapy in childhood cancer. J Pediatr Hematol Oncol. 2007;29:355-360. https://doi.org/10.1097/MPH.0b013e318059c220
  6. Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinumchemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol. 2005;23:8588-8596. https://doi.org/10.1200/JCO.2004.00.5355
  7. Kushner BH, Budnick A, Kramer K, Modak S, Cheung NK. Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer. 2006;107:417-422. https://doi.org/10.1002/cncr.22004
  8. Blakley BW, Gupta AK, Myers SF, Schwan S. Risk factors for ototoxicity due to cisplatin. Arch Otolaryngol Head Neck Surg. 1994;120:541-546.
  9. Bertolini P, Lassalle M, Mercier G, Raquin MA, Izzi G, Corradini N, Hartmann O. Platinum compound-related ototoxicity in children: longterm follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol. 2004;26:649-655. https://doi.org/10.1097/01.mph.0000141348.62532.73
  10. Kriukov AI, Kunel’skaia NL, Abramov VYu, Temnov AA, Levina YuV, Kudeeva YaYu, Baibakova EV, Chugunova MA. The ototoxic action of cisplatin on the middle ear. Vestnik Otorinilaringologii. 2015;80(1):21-24. (In Russ.) https://doi.org/10.17116/otorino201580121-24
  11. Lanvers-Kaminsky C, Ciarimboli G. Pharmacogenetics of drug-induced ototoxicity caused by aminoglycosides and cisplatin. Pharmacogenomics. 2017;18(18):1683-1695. https://doi.org/10.2217/pgs-2017-0125
  12. Bogomil’skiĭ MR, D’iakonova IN, Rakhmanova IV, Sapozhnikov YaM, Stakhovskaia OA, Tikhomirov AM. Electrophysiological evaluation of the hearing function following cisplatin administration. Vestnik otorinolaringologii. 2010;3:24-26. (InRuss.)
  13. Schacht J, Talaska AE, Rybak LP. Cisplatin and aminoglycoside antibiotics: hearing loss and its prevention. Anatomical Record. 2012;295(11):1837-1850. https://doi.org/10.1002/ar.22578.
  14. Kudeeva YaYu. Patogeneticheskie osobennosti porazheniya perifericheskogo otdela slukhovogo analizatora pod vozdeistviem tsisplatina (kliniko-eksperimental’noe issledovanie): Dis... kand. med. nauk. M. 2015. (InRuss.)
  15. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discovery. 2005;4(4):307-320. https://doi.org/10.1038/nrd1691
  16. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22(47):7265-7279. https://doi.org/10.1038/sj.onc.1206933
  17. Thomas JP, Lautermann J, Liedert B, Seiler F, Thomale J. High accumulation of platinum-DNA adducts in strial marginal cells of the cochlea is an early event in cisplatin but not carboplatin ototoxicity. Mol Pharmacol. 2006;70(1):23-29. https://doi.org/10.1124/mol.106.022244
  18. Langer T, am Zehnhoff-Dinnesen A, Radtke S, Meitert J, Zolk O. Understanding platinum-induced ototoxicity. Trends Pharmacol Sci. 2013;34(8):458-469. https://doi.org/10.1016/j.tips.2013.05.006
  19. Bokemeyer C, Berger CC, Hartmann JT, Kollmannsberger C, Schmoll HJ, Kuczyk MA, Kanz L. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer. 1998;77:1355-1362.
  20. Bhandare N, Antonelli PJ, Morris CG, Malayapa RS, Mendenhall WM. Ototoxicity after radiotherapy for head and neck tumors. Int J Radiat Oncol Biol Phys. 2007;67:469-479. https://doi.org/10.1016/j.ijrobp.2006.09.017
  21. Chang KW, Chinosornvatana N. Practical grading system for evaluating cisplatin ototoxicity in children. J Clin Oncol. 2010;28:1788—1795. https://doi.org/10.1200/JCO.2009.24.4228
  22. Pan CC, Eisbruch A, Lee JS, Snorrason RM, Ten Haken RK, Kileny PR. Prospective study of inner ear radiation dose and hearing loss in head-andneck cancer patients. Int J Radiat Oncol Biol Phys. 2005;61:1393-1402. https://doi.org/10.1016/j.ijrobp.2004.08.019
  23. Veenstra DL, Harris J, Gibson RL, Rosenfeld M, Burke W, Watts C. Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes. Genet Med. 2007;9:695-704. https://doi.org/10.1097GIM.0b013e318156dd07
  24. Waguespack JR, Ricci AJ. Aminoglycoside ototoxicity: permeant drugs cause permanent hair cell loss. J Physiol (Lond.). 2005;567:359-360. https://doi.org/10.1113/jphysiol.2005.094474
  25. van As JW, van den Berg H, van Dalen EC. Platinum-induced hearing loss after treatment for childhood cancer. Cochrane 8, CD010181(2016). https://doi.org/10.1038/clpt.2013.80
  26. Ross CJ, Katzov-Eckert H, Dubé MP, Brooks B, Rassekh SR, Barhdadi A, Feroz-Zada Y, Visscher H, Brown AM, Rieder MJ, Rogers PC, Phillips MS, Carleton BC, Hayden MR; CPNDS Consortium. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet. 2009;41(12):1345-1349. https://doi.org/10.1038/ng.478
  27. Pussegoda K, Ross CJ, Visscher H, Yazdanpanah M, Brooks B, Rassekh SR, Zada YF, Dubé MP, Carleton BC, Hayden MR; CPNDS Consortium. Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children. Clin Pharmacol Ther. 2013;94(2):243-251.
  28. Yang JJ, Lim JY, Huang J, Bass J, Wu J, Wang C, Fang J, Stewart E, Harstead EH, ES, Robinson GW, Evans WE, Pappo A, Zuo J, Relling MV, Onar-Thomas A, Gajjar A, Stewart CF. The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. Clin Pharmacol Ther. 2013;94(2):252-259. https://doi.org/10.1038/clpt.2013.121
  29. Lanvers-Kaminsky C, Malath I, Deuster D, Ciarimboli G, Boos J, Am Zehnhoff-Dinnesen AG. Evaluation of pharmacogenetic markers to predict the risk of Cisplatin-induced ototoxicity. Clin Pharmacol Ther. 2014;96(2):156-157. https://doi.org/10.1038/clpt.2014.67
  30. Stepanova AA, Sokolova M, Tverskaya SM, Polyakov AV. MLPA PCR-analysis for registration of the most frequent mutations in PAH gene. Med Gen. 2010;9(11):22-26.
  31. Bliznetz EA, Tverskaya SM, Zinchenko RA, Abrukova AV, Savaskina EN, Nikulin MV, Kirillov AG, Ginter EK, Polyakov AV. Genetic analysis of autosomal recessive osteopetrosis in Chuvashiya: the unique splice site mutation in TCIRG1 gene spread by the founder effect. Eur J Hum Genet. 2009;17(5):664-672. https://doi.org/10.1038/ejhg.2008.234
  32. Platinol [package insert]. Sermoneta-Latina, Italy: Corden Pharma Latina SpA.; 2011.
  33. Xu H, Robinson GW, Huang J, Lim JY, Zhang H, Bass JK, Broniscer A, Chintagumpala M, Bartels U, Gururangan S, Hassall T, Fisher M, Cohn R, Yamashita T, Teitz T, Zuo J, Onar-Thomas A, Gajjar A, Stewart CF, Yang JJ. Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. Nat Genet. 2015;47(3):263-266. https://doi.org/10.1038/ng.3217
  34. Vos HI, Guchelaar HJ, Gelderblom H, de Bont ES, Kremer LC, Naber AM, Hakobjan MH, van der Graaf WT, Coenen MJ, te Loo DM. Replication of a genetic variant in ACYP2 associated with cisplatin-induced hearing loss in patients with osteosarcoma. Pharmacogenet Genom. 2016;26(5):243-247. https://doi.org/10.1097/FPC.0000000000000212
  35. Drögemöller BI, Monzon JG, Bhavsar AP, Borrie AE, Brooks B, Wright GEB, Liu G, Renouf DJ, Kollmannsberger CK, Bedard PL, Aminkeng F, Amstutz U, Hildebrand CA, Gunaretnam EP, Critchley C, Chen Z, Brunham LR, Hayden MR, Ross CJD, Gelmon KA, Carleton BC. Association between SLC16A5 genetic variation and cisplatin-induced ototoxic effects in adult patients with testicular cancer. JAMA Oncol. 2017;3(11):1558-1562. https://doi.org/10.1001/jamaoncol.2017.0502
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.